Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF ASIA-PACIFIC ENTERAL FEEDING FORMULA MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE ASIA-PACIFIC ENTERAL FEEDING FORMULA MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.12 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 ASIA-PACIFIC ENTERAL FEEDING FORMULA MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
5.1 PESTEL ANALYSIS
5.2 PORTER'S FIVE FORCES MODEL
6 INDUSTRY INSIGHTS
6.1 MICRO AND MACRO ECONOMIC FACTORS
6.2 PENETRATION AND GROWTH PROSPECT MAPPING
6.3 KEY PRICING STRATEGIES
6.4 INTERVIEWS WITH SPECIALIST
6.5 ANALYSIS AND RECOMMENDATIONS
7 INTELLECTUAL PROPERTY (IP) PORTFOLIO
7.1 PATENT QUALITY AND STRENGTH
7.2 PATENT FAMILIES
7.3 LICENSING AND COLLABORATIONS
7.4 COMPETITIVE LANDSCAPE
7.5 IP STRATEGY AND MANAGEMENT
7.6 OTHER
8 COST ANALYSIS BREAKDOWN
9 TECHNOLOGY ROADMAP
10 INNOVATION TRACKER AND STRATEGIC ANALYSIS
10.1 MAJOR DEALS AND STRATEGIC ALLIANCES ANALYSIS
10.1.1 JOINT VENTURES
10.1.2 MERGERS AND ACQUISITIONS
10.1.3 LICENSING AND PARTNERSHIP
10.1.4 TECHNOLOGY COLLABORATIONS
10.1.5 STRATEGIC DIVESTMENTS
10.2 NUMBER OF PRODUCTS IN DEVELOPMENT
10.3 STAGE OF DEVELOPMENT
10.4 TIMELINES AND MILESTONES
10.5 INNOVATION STRATEGIES AND METHODOLOGIES
10.6 RISK ASSESSMENT AND MITIGATION
10.7 MERGERS AND ACQUISITIONS
10.8 FUTURE OUTLOOK
11 EPIDEMIOLOGY
11.1 INCIDENCE OF ALL BY GENDER
11.2 TREATMENT RATE
11.3 MORTALITY RATE
11.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL
11.5 PATIENT TREATMENT SUCCESS RATES
12 REGULATORY COMPLIANCE
12.1 REGULATORY AUTHORITIES
12.2 REGULATORY CLASSIFICATIONS
12.2.1 CLASS I
12.2.2 CLASS II
12.2.3 CLASS III
12.3 REGULATORY SUBMISSIONS
12.4 INTERNATIONAL HARMONIZATION
12.5 COMPLIANCE AND QUALITY MANAGEMENT SYSTEMS
12.6 REGULATORY CHALLENGES AND STRATEGIES
TABLE 1 CLINICAL TRIAL MARKET
Company Name Product Name
XX XX
XX XX
XX XX
XX XX
XX XX
XX XX
XX XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 2 DISTRIBUTION OF PRODUCTS AND PROJECTS BY PHASE
Phase Number of Projects
Preclinical/Research Projects XX
Clinical Development XX
Phase I XX
Phase II XX
Phase III XX
U.S. Filed/Approved but Not Yet Marketed XX
Total XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 3 DISTRIBUTION OF PROJECTS BY THERAPEUTIC AREA AND PHASE
Therapeutic Area Preclinical/ Research Project
XX XX
XX XX
XX XX
XX XX
XX XX
Total Projects XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 4 DISTRIBUTION OF PROJECTS BY SCIENTIFIC APPROACH AND PHASE
Technology Preclinical/ Research Project
XX XX
XX XX
XX XX
XX XX
XX XX
Total Projects XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
FIGURE 1 TOP ENTITIES BASED ON R&D GLANCE
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
13 REIMBURSEMENT FRAMEWORK
14 OPPUTUNITY MAP ANALYSIS
15 VALUE CHAIN ANALYSIS
16 HEALTHCARE ECONOMY
16.1 HEALTHCARE EXPENDITURE
16.2 CAPITAL EXPENDITURE
16.3 CAPEX TRENDS
16.4 CAPEX ALLOCATION
16.5 FUNDING SOURCES
16.6 INDUSTRY BENCHMARKS
16.7 GDP RATION IN OVERALL GDP
16.8 HEALTHCARE SYSTEM STRUCTURE
16.9 GOVERNMENT POLICIES
16.1 ECONOMIC DEVELOPMENT
17 ASIA-PACIFIC ENTERAL FEEDING FORMULA MARKET, BY PRODUCT
17.1 OVERVIEW
17.2 STANDARD FORMULAS
17.2.1 CALORIE
17.2.1.1. 1.0 KCAL/ML
17.2.1.2. 1.2 KCAL/ML
17.2.1.3. 1.5 KCAL/ML
17.2.1.4. 2.0KCAL/ML
17.2.2 DISEASE
17.2.2.1. DIABETIC FORMULAS
17.2.2.2. RENAL FORMULAS
17.2.2.3. HEPATIC FORMULAS
17.2.2.4. PULMONARY FORMULAS
17.2.2.5. OTHERS
17.3 PEPTIDES FORMULAS
17.3.1 CALORIE
17.3.1.1. 1.0 KCAL/ML
17.3.1.1.1. MARKET VALUE(USD MILLION)
17.3.1.1.2. MARKET VOLUME(UNITS)
17.3.1.1.3. AVERAGE SELLING PRICE(USD)
17.3.1.2. 1.2 KCAL/ML
17.3.1.2.1. MARKET VALUE(USD MILLION)
17.3.1.2.2. MARKET VOLUME(UNITS)
17.3.1.2.3. AVERAGE SELLING PRICE(USD)
17.3.1.3. 1.5 KCAL/ML
17.3.1.3.1. MARKET VALUE(USD MILLION)
17.3.1.3.2. MARKET VOLUME(UNITS)
17.3.1.3.3. AVERAGE SELLING PRICE(USD)
17.3.1.4. 2.0KCAL/ML
17.3.1.4.1. MARKET VALUE(USD MILLION)
17.3.1.4.2. MARKET VOLUME(UNITS)
17.3.1.4.3. AVERAGE SELLING PRICE(USD)
17.3.2 DISEASE
17.3.2.1. DIABETIC FORMULAS
17.3.2.2. RENAL FORMULAS
17.3.2.3. HEPATIC FORMULAS
17.3.2.4. PULMONARY FORMULAS
17.3.2.5. OTHERS
17.4 SPECIALISED FORMULAS
17.4.1 CALORIE
17.4.1.1. 1.0 KCAL/ML
17.4.1.1.1. MARKET VALUE(USD MILLION)
17.4.1.1.2. MARKET VOLUME(UNITS)
17.4.1.1.3. AVERAGE SELLING PRICE(USD)
17.4.1.2. 1.2 KCAL/ML
17.4.1.2.1. MARKET VALUE(USD MILLION)
17.4.1.2.2. MARKET VOLUME(UNITS)
17.4.1.2.3. AVERAGE SELLING PRICE(USD)
17.4.1.3. 1.5 KCAL/ML
17.4.1.3.1. MARKET VALUE(USD MILLION)
17.4.1.3.2. MARKET VOLUME(UNITS)
17.4.1.3.3. AVERAGE SELLING PRICE(USD)
17.4.1.4. 2.0KCAL/ML
17.4.1.4.1. MARKET VALUE(USD MILLION)
17.4.1.4.2. MARKET VOLUME(UNITS)
17.4.1.4.3. AVERAGE SELLING PRICE(USD)
17.4.2 DISEASE
17.4.2.1. DIABETIC FORMULAS
17.4.2.2. RENAL FORMULAS
17.4.2.3. HEPATIC FORMULAS
17.4.2.4. PULMONARY FORMULAS
17.4.2.5. OTHERS
18 ASIA-PACIFIC ENTERAL FEEDING FORMULA MARKET, BY APPLICATION
18.1 OVERVIEW
18.2 CRITICAL CARE
18.3 GASTROENTEROLOGY
18.4 ONCOLOGY
18.5 NEUROLOGY
18.6 DIABETES
18.7 OTHERS
19 ASIA-PACIFIC ENTERAL FEEDING FORMULA MARKET, BY TYPE OF TUBE FEEDING
19.1 OVERVIEW
19.2 GASTRIC TUBE FEEDING
19.3 NASOGASTRIC TUBE FEEDING
19.4 GASTROTOMY TUBE FEEDING
19.5 DUODENAL OR JEJUNAL TUBE FEEDING
20 ASIA-PACIFIC ENTERAL FEEDING FORMULA MARKET, BY STAGE
20.1 OVERVIEW
20.2 ADULT
20.3 PEDIATRIC
20.3.1 METABOLIC COMPICATIONS
20.3.2 FOOD ALLERGY
20.3.3 GASTROINTESTINAL DYSMOTILITY
20.3.4 INTRACTABLE DIARRHEA
20.3.5 INFECTIOUS COMPLICATIONS
20.3.6 BURN INJURY
20.3.7 CYSTIC FIBROSIS
20.3.8 CONGENITAL HEART DISEASE
20.3.9 CHRONIC RENAL/ PULMONARY DISEASE
20.3.10 CROHN’S DISEASE
20.3.11 OTHERS
21 ASIA-PACIFIC ENTERAL FEEDING FORMULA MARKET, BY END USER
21.1 OVERVIEW
21.2 HOSPITALS
21.3 LONG TERM CARE FACILITIES
21.3.1 HOME CARE AGENCIES AND HOSPICES
21.3.2 NURSING HOMES
21.3.3 ASSISTED LIVING FACILITIES
22 ASIA-PACIFIC ENTERAL FEEDING FORMULA MARKET, BY COUNTRY
22.1 ASIA-PACIFIC ENTERAL FEEDING FORMULA MARKET (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
22.1.1 ASIA-PACIFIC
22.1.1.1. JAPAN
22.1.1.2. CHINA
22.1.1.3. SOUTH KOREA
22.1.1.4. INDIA
22.1.1.5. AUSTRALIA
22.1.1.6. SINGAPORE
22.1.1.7. THAILAND
22.1.1.8. MALAYSIA
22.1.1.9. INDONESIA
22.1.1.10. PHILIPPINES
22.1.1.11. VIETNAM
22.1.1.12. REST OF ASIA-PACIFIC
23 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES ASIA-PACIFIC ENTERAL FEEDING FORMULA MARKET, COMPANY LANDSCAPE
23.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
23.2 MERGERS & ACQUISITIONS
23.3 NEW PRODUCT DEVELOPMENT & APPROVALS
23.4 EXPANSIONS
23.5 REGULATORY CHANGES
23.6 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
24 ASIA-PACIFIC ENTERAL FEEDING FORMULA MARKET, SWOT AND DBR ANALYSIS
25 ASIA-PACIFIC ENTERAL FEEDING FORMULA MARKET, COMPANY PROFILE
25.1 ABBOTT
25.1.1 COMPANY OVERVIEW
25.1.2 REVENUE ANALYSIS
25.1.3 GEOGRAPHIC PRESENCE
25.1.4 PRODUCT PORTFOLIO
25.1.5 RECENT DEVELOPMENTS
25.2 NESTLÉ
25.2.1 COMPANY OVERVIEW
25.2.2 REVENUE ANALYSIS
25.2.3 GEOGRAPHIC PRESENCE
25.2.4 PRODUCT PORTFOLIO
25.2.5 RECENT DEVELOPMENTS
25.3 MEIJI HOLDINGS CO., LTD.
25.3.1 COMPANY OVERVIEW
25.3.2 REVENUE ANALYSIS
25.3.3 GEOGRAPHIC PRESENCE
25.3.4 PRODUCT PORTFOLIO
25.3.5 RECENT DEVELOPMENTS
25.4 B. BRAUN MELSUNGEN AG
25.4.1 COMPANY OVERVIEW
25.4.2 REVENUE ANALYSIS
25.4.3 GEOGRAPHIC PRESENCE
25.4.4 PRODUCT PORTFOLIO
25.4.5 RECENT DEVELOPMENTS
25.5 DANONE NUTRICIA
25.5.1 COMPANY OVERVIEW
25.5.2 REVENUE ANALYSIS
25.5.3 GEOGRAPHIC PRESENCE
25.5.4 PRODUCT PORTFOLIO
25.5.5 RECENT DEVELOPMENTS
25.6 FRESENIUS SE & CO. KGAA
25.6.1 COMPANY OVERVIEW
25.6.2 REVENUE ANALYSIS
25.6.3 GEOGRAPHIC PRESENCE
25.6.4 PRODUCT PORTFOLIO
25.6.5 RECENT DEVELOPMENTS
25.7 OTSUKA PHARMACEUTICAL CO., LTD.
25.7.1 COMPANY OVERVIEW
25.7.2 REVENUE ANALYSIS
25.7.3 GEOGRAPHIC PRESENCE
25.7.4 PRODUCT PORTFOLIO
25.7.5 RECENT DEVELOPMENTS
25.8 GLOBAL HEALTH PRODUCTS, INC.
25.8.1 COMPANY OVERVIEW
25.8.2 REVENUE ANALYSIS
25.8.3 GEOGRAPHIC PRESENCE
25.8.4 PRODUCT PORTFOLIO
25.8.5 RECENT DEVELOPMENTS
25.9 HORMEL FOODS, LLC
25.9.1 COMPANY OVERVIEW
25.9.2 REVENUE ANALYSIS
25.9.3 GEOGRAPHIC PRESENCE
25.9.4 PRODUCT PORTFOLIO
25.9.5 RECENT DEVELOPMENTS
25.1 MEAD JOHNSON & COMPANY, LLC.
25.10.1 COMPANY OVERVIEW
25.10.2 REVENUE ANALYSIS
25.10.3 GEOGRAPHIC PRESENCE
25.10.4 PRODUCT PORTFOLIO
25.10.5 RECENT DEVELOPMENTS
25.11 MEDLINE INDUSTRIES, INC
25.11.1 COMPANY OVERVIEW
25.11.2 REVENUE ANALYSIS
25.11.3 GEOGRAPHIC PRESENCE
25.11.4 PRODUCT PORTFOLIO
25.11.5 RECENT DEVELOPMENTS
25.12 MEDTRITION, INC.
25.12.1 COMPANY OVERVIEW
25.12.2 REVENUE ANALYSIS
25.12.3 GEOGRAPHIC PRESENCE
25.12.4 PRODUCT PORTFOLIO
25.12.5 RECENT DEVELOPMENTS
NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST RELATED REPORTS
26 CONCLUSION
27 QUESTIONNAIRE
28 ABOUT DATA BRIDGE MARKET RESEARCH
